Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (102653)	6/16/2000 1:58:00 PM
From: Jenna	Read Replies (2) \| Respond to of 120523

<<Alert #5 earnings Play for June 22>> breakout on daily chart. Breaks through at 62 on a range expansion breakout, bullish divergence On Balance Volume is at an all time high even though prices are not. Strong money flow into this stock.

To: Jenna who wrote (102653)	6/16/2000 2:04:00 PM
From: johnsto1	Respond to of 120523

snps=ORCH(personalized,web based dna data for genomics)could be a ground gainer in a genomics rally Barrons 6-4-2000: Although Isaly owns his fair share of big multinationals -- Eli Lilly, Warner-Lambert and Pharmacia & Upjohn are among his favorites -- his true passion is for the smaller, more research-driven companies in the biotech area. The majority of his biotech holdings aren't pharmaceutical makers themselves, but outfits that are perfecting drug-discovery processes. One important part of the process is understanding the components of human genes, or genomics. Isaly compares gene sequencing to throwing disassembled parts of a Rolex watch on a table in front of you. "Do all the parts really add up to a Rolex?" Not yet, but it's a start. One of his favorite companies in this area, Orchid Biosciences, specializes in trying to sort out the extremely small differences in individuals' genes. From there, it seeks to figure out what they mean and how to use them to predict diseases. These differences are called single nucleotide polymorphisms, or SNPs, and Orchid specializes in identifying those SNPs and scoring them. Once the scores are developed, they can be used to discover drugs, design clinical trials, monitor patients, as well as breed plants and animals. A number of analysts see SNP-scoring technology as the next multibillion-dollar market opportunity within genomics.* Given this, Isaly thinks that Orchid, which went public last month -- and which Isaly has owned since it was a private company -- is a bargain.